🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New📰| Selective #CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive #BreastCancer | Full text in Clinical Cancer Research. Cristina Guarducci Rinath Jeselsohn Geoffrey Shapiro MD PhD Albert Grinshpun ➡️pubmed.ncbi.nlm.nih.gov/38381406/

Published today! We found that cancer cells adapting to drug treatments don't simply switch from a sensitive to resistant state; instead there's a ‘resistance continuum’ of resistant phenotypes with epigenetically reprogrammed states. 🧵⬇️ nature.com/articles/s4158… @Gustavo_SFranca

Insights on PARPi in adv HGSOC: efficacy independent of BRCA domain defects or mutation types. Numerically longer mPFS in pts with DBD defects. Check our new study in Frontiers - Oncology! #OvarianCancer #PARPinhibitors Thanks to Carmine De Angelis and all co-authors. frontiersin.org/journals/oncol…

Here we go! Grazia Arpino ESMO - Eur. Oncology #ESMO2024 🌋

Super MV Dieci - TILs in the ShortHer trial! 👏🏻👏🏻👏🏻🔝🔝Maria Vittoria Dieci #ESMO24

Superb presentation of the Rome trial by Andrea Botticelli during the Presidential Session III at #ESMO24 🔝🇮🇹 congratulations 👏🏻 Andrea

Online Now: The hallmarks of cancer immune evasion dlvr.it/TFFy1H

ALTTO trial: years of work from many investigators and 8.381 #patients with #HER2-positive early #breastcancer Breast International Group Institut Jules Bordet Instituut Dana-Farber Mayo Clinic Frontier Science Scotland, Harvard Medical School Elsevier ESMO Open GSK Pfizer Inc. esmoopen.com/article/S2059-…

⬇️New Publication 🚨 We conducted a systematic review and meta-analysis evaluating the combination of ADCs and ICIs in solid tumors. Findings show comparable safety to monotherapy, but increased risks for ILD/pneumonitis. #Immunotherapy OncoAlert Medscape Oncology CancerTherapyAdvisor

Our systematic review and meta-analysis just out on EJC. Are there any differences in PFS assessment by BICR and local investigator? Thanks to all co-authors! ejcancer.com/article/S0959-…

Had an amazing debate with Carmine De Angelis at Emirates Oncology (MonarchE vs. NATALEE).

The duration of tumor control with CDK4/6i-based therapy + the presence of visceral metastases emerged as key factors that may affect treatment decision in patients with hormone receptor–positive, ERBB2–negative metastatic breast cancer. ja.ma/41dn2Ir Dario Trapani G Curigliano MD PhD

Leonardo Provenzano Maria Vittoria Dieci Andrea Botticelli Matteo Lambertini, MD PhD Alessandra Gennari MD PhD Angela Toss Daniele Generali Gaia Griguolo Carmine De Angelis Grazia Arpino Carmen Criscitiello Giancarlo Pruneri

The title of the #ASCO25 abstracts are now out...very excited that the #BRCABCYcollaboration will contribute with 2 oral presentations...looking forward to being there! Eva Blondeaux Angela Toss Paola Zagami, MD Carmine De Angelis OncoAlert Università di Genova Ospedale San Martino Genova Conquer Cancer, the ASCO Foundation ASCO

NEXT Oncology is back! L’evento che esplora l’innovazione in oncologia ritorna a Milano nei giorni 9 e 10 maggio. Tra i tanti argomenti si parlerà di profilazione omica, #microbioma, immunità antitumorale, #AI, Anticorpi Farmaco Coniugati (#ADC) e strategie per il finanziamento e

Excellent review of post CDK4/6i tx in challenging scenarios. A must read for all breast oncologists! Congrats to Roberto Buonaiuto, Carmine De Angelis and all co-authors.

Dear Colleagues at #ASCO25 An honor to present Angela Toss Presenting on Association between type of BRCA1/2 pathogenic/likely pathogenic variants and outcome in young patients with #BreastCancer Eva Blondeaux Cynthia Villarreal-Garza, MD DSc Carmine De Angelis Elisa Agostinetto Breast Cancer

Thanks to Matteo Lambertini, MD PhD for two amazing days in Genova for #YBO. Outstanding presentations 📚 Lots of friends 👨🏼‍🔬🧑‍🔬🧑‍🏫 Inspiring networking 🔗